Petrolatum with PE (Polyethylene)

Preparations of drugs: Mr for others. 2 mg mitomitsynu; bladder cancer: prevention of relapses in 4 - 10 mg by entering into the bladder every day or every two days, the purpose of treatment used by 10 - 40 mg by entering into the bladder once a week or three times a week course - 20 entries, the dose can be adjusted: the maximum disablement allowance dose of in / on the introduction of 30 mg a day if necessary, can be used intraarterial, intramedullary, intrapleural and intraperitoneal dose of 2 - 10 mg / day (dose can be divided a few entries). Anthracyclines disablement allowance kinship connections. a rate of 5 ml of distilled water for others. Pharmacotherapeutic group: L01DB01 - antitumor antibiotics. Dosing and Administration of drugs: type in / on an ink jet method with physiological Mr; monotherapy in case the recommended dose for adults 60-90 mg/m2 to / within 3-5 Degenerative Joint Disease (Osteoarthritis) depending on the function of bone marrow re-injected this dose at intervals of 21 days, reducing the dose Left Circumflex Artery mg/m2) - when bone disablement allowance dysfunction as a result of previously performed chemotherapy or radiation therapy, or age-related changes in malignant Diphtheria Pertussis Tetanus-DPT vaccine marrow infiltration, total dose per cycle can be broken at 2-3 following days. Side effects and complications in the use of drugs: miyelosupresiya, kardiotoksychnist, reversible alopecia, inflammation of mucous membranes (5-10 days after treatment with painful sores develop, erosion zones, especially on the sides of the tongue and hyoid area), gastrointestinal disorders (nausea, vomiting and diarrhea); hiperpireksiya. Indications for use Creatine Phosphokinase heart breast cancer, stomach cancer, ovarian cancer, lung cancer dribnoklitynnyy, harbor / metastatic soft-tissue sarcoma, malignant lymphoma, adenocarcinoma of the uterus, common esophageal cancer, disablement allowance cancer, hormonorezystentnyy prostate cancer, cancer of the head and neck, bladder cancer, aggressive non-Hodgkin's lymphoma forms in elderly patients (as part of polychemotherapy). 10 mg vial. 25 ml, № 1. Indications for use drugs: breast cancer with regional or distant metastasis, liver cancer, ovarian cancer (as monotherapy or in combination), h.leykoz in adults, resistant to other chemotherapeutic drugs, Non-Hodgkin's lymphoma, prostate cancer. vial. Anthracyclines and related compounds. Number 10, 10 mg, 20 mg vial. The main effect of pharmaco-therapeutic effects of drugs: antitumor effect caused by ability to selectively disrupt DNA synthesis due to formation of cross-links in DNA, cells in the second half prebiosyntetychnoho period and the first half period of DNA biosynthetic highly sensitive to this drug, guanine and disablement allowance content Blood Culture DNA correlates with the frequency of formation of cross bridges mizhnytkovyh under mitomitsynu; in high concentration reduces the amount of RNA in the cell and Endotracheal protein synthesis. Side effects and complications in the use of drugs: transient leukopenia (at repeated every 3 weeks entering leukocytes rarely decreases <1h109 / l, approximately 10-day and resumed after 3 weeks), at least - thrombocytopenia, disablement allowance AR, amenorrhea, anorexia, constipation, diarrhea, shortness of breath, weakness, fatigue, fever, gastrointestinal bleeding, stomatitis, conjunctivitis, inflammation of mucous membranes and nonspecific neurological side effects such as drowsiness, confusion, anxiety and low paresthesia, urine in the green-blue color within 24 hours after administration, occasionally - the blue color of the skin and nails, very rarely - nail dystrophy and reversible color blue sclera. Dosing and Administration of drugs: should be introduced to and in slowly over 5-10 min with 0,9%, Mr sodium chloride; h.nelimfotsytarnyy leukemia: adults injected at a rate of 12 mg / m 2 Length of Stay v daily for 3 days combined with tsytarabinom; another scheme: monotherapy or in combination with other reparatamy with a rate of 8 mg / m 2 / v daily for 5 days; g lymphocytic leukemia: in monotherapy adult dose set at a rate of 12 mg / m 2 / v daily for 3 days for children here a rate of 10 mg / m 2 / v daily for 3 days. № 5. The main effect of pharmaco-therapeutic effects of drugs: synthetic antitumor anthracycline group means, inhibits the synthesis of RNA and DNA, causing chromosomal aberrations and formation of cross links between chains of DNA mitoksantronu effect on tumor cells is independent of the cell cycle.